Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2024 | $20.00 | Sector Outperform | Scotiabank |
| 9/10/2024 | $15.00 | Mkt Outperform | JMP Securities |
| 7/9/2024 | $18.00 | Buy | Craig Hallum |
| 5/23/2024 | $21.00 | Overweight | Cantor Fitzgerald |
SC 13G - Skye Bioscience, Inc. (0001516551) (Subject)
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing cli
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. "Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions," said Punit Dhillon, CEO of Skye. "In Q2, at our event, ‘Metabolic Rewiring wi
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company's operational and clinical expertise. Our strategic focus on the Nimacimab metabolic program will be supported by an evolving board as Keith Ward, PhD, and Praveen Tyle, PhD, resign from their roles as Boa
Scotiabank initiated coverage of Skye Bioscience with a rating of Sector Outperform and set a new price target of $20.00
JMP Securities initiated coverage of Skye Bioscience with a rating of Mkt Outperform and set a new price target of $15.00
Craig Hallum initiated coverage of Skye Bioscience with a rating of Buy and set a new price target of $18.00
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
Peripherally-restricted nimacimab achieves significant dose-dependent weight loss, fat mass reduction, lean mass preservation, and glycemic control in diet-induced obesity model Preliminary data shows that nimacimab achieves desired metabolic outcomes without central inhibition and its risk of neuropsychiatric adverse events SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced preliminary data from a diet-induced obesity (DIO) model in mice. Skye's CB1-inhibiting antibody, nimacimab, achieved significant dose-dependent weight
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Following the call, a replay and transcript will be available at the same website.
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skye's new Chairman of the Board, effective October 25, 2024. Mr. Grayson currently serves as a member of Skye's Audit, Compensation and Nominating and Corporate Governance Committees. Punit Dhillon, Skye's Chief Executive Officer, will continue to serve as a member of the Board. Punit Dhillon, Skye's Chief Executive Officer and former Chairman of the Board, commented, "We have a high bar with respect to how
8-K - Skye Bioscience, Inc. (0001516551) (Filer)
8-K - Skye Bioscience, Inc. (0001516551) (Filer)
DEF 14A - Skye Bioscience, Inc. (0001516551) (Filer)
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Following the call, a replay and transcript will be available at the same website.
Craig-Hallum analyst Albert Lowe initiates coverage on Skye Bioscience (NASDAQ:SKYE) with a Buy rating and announces Price Target of $18.